Alzheimer's CSF markers in older schizophrenia patients

International Journal of Geriatric Psychiatry

Volumn 26, Issue 6, 2011, Pages 640-648

  Frisoni, Giovanni B ^a,b   Prestia, Annapaola ^a   Geroldi, Cristina ^a,b   Adorni, Andrea ^a,b   Ghidoni, Roberta ^c,d   Amicucci, Giovanni ^e   Bonetti, Matteo ^f   Soricelli, Andrea ^g   Rasser, Paul E ^h,i   Thompson, Paul M ^j   Giannakopoulos, Panteleimon ^k,l  

^a LENITEM Laboratory of Epidemiology Neuroimaging and Telemedicine   (Italy)

^b Psychogeriatric Ward ^*  (Italy)

^c Proteomics Unit   (Italy)

^d IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^e S Orsola Hospital   (Italy)

^f Neuroradiology Service   (Italy)

^g UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^h SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

ⁱ UNIVERSITY OF NEWCASTLE   (Australia)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

Abeta42; Alzheimer disease; Brodmann areas; CSF; schizophrenia; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; LUMBAR PUNCTURE; MALE; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; SCHIZOPHRENIA;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PEPTIDE FRAGMENTS; SCHIZOPHRENIA; TAU PROTEINS;

EID: 79953808975     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2575     Document Type: Article

References (45)

1. Arnold SE, Trojanowski JQ, Gur RE, et al,. 1998. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 55: 225-232.
2. Bertrand J, Plouffe V, Sénéchal P, et al,. 2010. The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. Neuroscience 168: 323-334.
3. Blennow K, Vanmechelen E, Hampel H,. 2001. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24: 87-97. (Pubitemid 34066679)
4. Buerger K, Teipel SJ, Zinkowski R, et al,. 2002. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59: 627-629. (Pubitemid 34920005)
5. Casanova MF, Carosella NW, Gold JM, et al,. 1993. A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia. Psychiatry Res 49: 41-62. (Pubitemid 23329246)
6. Dubois B, Feldman HH, Jacova C, et al,. 2007. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746. (Pubitemid 47058377)
7. Dwork AJ, Susser ES, Keilp J, et al,. 1998. Senile degeneration and cognitive impairment in chronic schizophrenia. Am J Psychiatry 155: 1536-1543. (Pubitemid 28512021)
8. Friedman JI, Harvey PD, Coleman T, et al,. 2001. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am J Psychiatry 158: 1441-1448. (Pubitemid 32847243)
9. Frisoni GB, Pievani M, Testa C, et al,. 2007. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 130: 720-730. (Pubitemid 46410740)
10. Frisoni GB, Prestia A, Adorni A, et al,. 2009a. In vivo neuropathology of cortical changes in elderly persons with schizophrenia. Biol Psychiatry 66: 578-585.
11. Frisoni GB, Prestia A, Zanetti O, et al,. 2009b. Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer &Dementia 5: 307-317.
12. Frisoni GB, Galluzzi S, Signorini M, et al,. 2009c. Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis. Report of 2 cases. Alzheimer Dis Assoc Disord 24: 108-114.
13. Fucetola R, Seidman LJ, Kremen WS, et al,. 2000. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 48: 137-146. (Pubitemid 30618803)
14. Goldberg TE, Gold JM,. 1995. Neurocognitive deficits in schizophrenia. In, Hirsch SR, Weinberger DR, (eds). Schizophrenia. Oxford: Blackwell; 146-162.
15. Goldman AL, Pezawas L, Mattay VS, et al,. 2008. Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. Biol Psychiatry 63: 475-483. (Pubitemid 351227357)
16. Gong CX, Shaikh S, Grundke-Iqbal I, et al,. 1996. Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics. Brain Res 741: 95-102. (Pubitemid 26426303)
17. He J, Luo H, Yan B, et al,. 2009. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 30: 1205-1216.
18. Heaton R, Paulsen JS, McAdams LA, et al,. 1994. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry 5: 469-476. (Pubitemid 24180493)
19. Higaki J, Murphy GM Jr, Cordell BJ,. 1997. Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. Neurochemistry 68: 333-336. (Pubitemid 26427325)
20. Jaaro-Peled H, Hayashi-Takagi A, Seshadri S, et al,. 2009. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci 32: 485-495.
21. Jabben N, Arts B, van Os J, Krabbendam L,. 2010. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder. J Clin Psychiatry 71: 764-774.
22. Jagust WJ, Landau SM, Shaw LM, et al,. 2009. Alzheimer's Disease neuroimaging initiative. Relationships between biomarkers in aging and dementia. Neurology 73: 1193-1199.
23. Jahshan C, Heaton RK, Golshan S, Cadenhead KS,. 2010. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology 24: 109-120.
24. Lezak M, Howieson D, Loring DW,. 2004. Neuropsychological Assessment, 4th edn. University Press: Oxford.
25. Lovestone S, Reynolds CH,. 1997. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324. (Pubitemid 27170324)
26. Mattsson N, Zetterberg H, Hansson O, et al,. 2009. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393.
27. Nishioka N, Arnold SE,. 2004. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 12: 167-175. (Pubitemid 38250300)
28. Pikkarainen M, Kauppinen T, Alafuzoff I,. 2009. Hyperphosphorylated tau in the occipital cortex in aged nondemented subjects. J Neuropathol Exp Neurol 68: 653-660.
29. Powchik P, Davidson M, Haroutunian V, et al,. 1998. Postmortem studies in schizophrenia. Schizophr Bull 24: 325-341. (Pubitemid 28378220)
30. Preuss U, Mandelkow EM,. 1998. Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer's disease. Eur J Cell Biol 76: 176-184. (Pubitemid 28365356)
31. Purohit DP, Perl DP, Haroutunian V, et al,. 1998. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 55: 205-211.
32. Rasser PE, Johnston PJ, Ward PB, et al,. 2004. A deformable Brodmann area atlas. IEEE International Symposium on Biomedical Imaging: Macro to Nano, Arlington, VA, USA. IEEE International Symposium on 15-18 April 2004; 400-403. (Pubitemid 40513959)
33. Religa D, Laudon H, Styczynska M, et al,. 2003. Amyloid beta pathology in Alzheimer's disease and schizophrenia. Am J Psychiatry 160: 867-872. (Pubitemid 41079570)
34. Savonenko AV, Melnikova T, Laird FM, et al,. 2008. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA 105: 5585-5590. (Pubitemid 351753906)
35. Sawada K, Barr AM, Nakamura M, et al,. 2005. Hippocampal complex in proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry 62: 263-272. (Pubitemid 40990971)
36. Schönknecht P, Hempel A, Hunt A, et al,. 2003a. Cerebrospinal fluid tau protein levels in schizophrenia. Eur Arch Psychiatry Clin Neurosci 253: 100-102. (Pubitemid 37205485)
37. Schönknecht P, Pantel J, Hartmann T, et al,. 2003b. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res 120: 231-238. (Pubitemid 38366050)
38. Shattuck DW, Leahy RM,. 2001. Automated graph-based analysis and correction of cortical volume topology. IEEE Trans Med Imaging 20: 1167-1177. (Pubitemid 33106070)
39. Sheline YI, Raichle ME, Snyder AZ, et al,. 2010. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 67: 584-587.
40. Sjögren M, Vanderstichele H, Agren H, et al,. 2001. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47: 1776-1781. (Pubitemid 32881189)
41. Sowell ER, Thompson PM, Rex D, et al,. 2001. Mapping continued brain growth and gray matter density reduction in dorsal frontal cortex: inverse relationships during post-adolescent brain maturation. J Neurosci 21: 8819-8829. (Pubitemid 33054846)
42. Thompson PM, Hayashi KM, de Zubicaray G, et al,. 2003. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 23: 994-1005. (Pubitemid 36206191)
43. Thompson PM, Hayashi KM, De Zubicaray GI, et al,. 2004. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 22: 1754-1766. (Pubitemid 38962663)
44. Tsuang M,. 2000. Schizophrenia: genes and environment. Biol Psychiatry. 47: 210-220. (Pubitemid 30077397)
45. Wisniewski T, Konietzko U,. 2008. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 7: 805-811.